CASI Pharmaceuticals, Inc. (CASI)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CASI Pharmaceuticals, Inc. (CASI) trades at $0.15 with AI Score 47/100 (Grade C). CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics primarily in China and the United States. Market cap: $2.33M, Sector: Healthcare.
Price live · AI analysis from May 9, 2026Analyst Coverage for CASI: CASI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CASI against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CASI: the 1 perspectives are evenly split.
How is this calculated? →CASI Pharmaceuticals, Inc. (CASI) Healthcare & Pipeline Overview
CASI Pharmaceuticals, Inc. develops and commercializes pharmaceutical products, focusing on hematological cancers. With a pipeline including EVOMELA and CNCT19, CASI targets markets in China, the United States, and internationally, navigating the competitive biotechnology landscape with licensing and distribution agreements.
What Is the Investment Thesis for CASI?
CASI Pharmaceuticals presents a focused investment opportunity within the biopharmaceutical sector, primarily targeting the Chinese and U.S. markets. A key value driver is the advancement of its pipeline, particularly CNCT19, a CAR-T therapy, and BI-1206, an anti-FcγRIIB antibody, both in clinical trials. Successful clinical trial outcomes and subsequent regulatory approvals could significantly increase shareholder value. The company's existing commercial product, EVOMELA, provides a revenue stream, although its profitability is constrained by a negative profit margin of -183.9%. Growth catalysts include potential partnerships and licensing agreements, as well as expansion into new therapeutic areas. Potential risks include clinical trial failures, regulatory hurdles, and competition from established players in the oncology market. The company's beta of 0.89 suggests lower volatility compared to the broader market.
Based on FMP financials and quantitative analysis
CASI Key Highlights
- Market capitalization of $2.33M indicates a small-cap company with potential for growth but also higher risk.
- Gross margin of 35.8% reflects the company's ability to generate revenue from its product sales, although this needs to translate into overall profitability.
- Profit margin of -183.9% highlights significant challenges in achieving profitability, requiring close monitoring of operating expenses and revenue growth.
- The company has 233 employees, indicating a relatively lean operation for a biopharmaceutical company with both development and commercialization activities.
- CASI has multiple licensing and distribution agreements, suggesting a strategic approach to expanding its market reach and product portfolio.
Who Are CASI's Competitors?
CASI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GILD Gilead Sciences, Inc. | $129.03 | -1.70% | $160.20B | 94 |
| BMY Bristol-Myers Squibb Company | $56.73 | -2.40% | $115.86B | 88 |
| JNJ Johnson & Johnson | $258.13 | -1.87% | $621.38B | 90 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CASI's Key Strengths?
- Diverse product pipeline targeting hematological cancers.
- Strategic partnerships and licensing agreements.
- Focus on the Chinese market.
- Commercialized product (EVOMELA) generating revenue.
What Are CASI's Weaknesses?
- Negative profit margin.
- Reliance on clinical trial success.
- Limited financial resources compared to larger competitors.
- Dependence on regulatory approvals.
What Could Drive CASI Stock Higher?
- Clinical trial results for CNCT19 in B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL).
- Data readouts from Phase I/II trials of BI-1206 in combination with anti-PD1 therapy Keytruda for solid tumors.
- Regulatory submissions for key pipeline products in China and the United States.
- Expansion of strategic partnerships and licensing agreements to enhance the product portfolio.
- Commercialization efforts for EVOMELA in existing and new markets.
What Are the Key Risks for CASI?
- Financial-distress signal — its Altman Z-Score of -47.99 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for key pipeline products, leading to delays or discontinuation of development.
- Regulatory hurdles and delays in obtaining approvals for new therapies.
- Competition from established pharmaceutical companies with greater resources and market share.
- Dependence on strategic partnerships and licensing agreements, which could be terminated or altered.
- Economic and political instability in China, impacting market access and commercial operations.
What Are the Growth Opportunities for CASI?
- Expansion of CNCT19 CAR-T Therapy: CASI's CNCT19, an autologous CD19 CAR-T investigative product, represents a significant growth opportunity in treating B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). The CAR-T therapy market is projected to grow substantially, driven by the increasing prevalence of hematological malignancies and the high efficacy of CAR-T therapies. Successful clinical trials and regulatory approval in China and the United States could lead to substantial revenue growth for CASI. Timeline: Ongoing clinical trials with potential for regulatory submissions within the next 2-3 years.
- Development of BI-1206 in Combination Therapies: BI-1206, currently in Phase I/II trials in combination with anti-PD1 therapy Keytruda for solid tumors and with MabThera (rituximab) for relapsed/refractory NHL, offers a promising growth avenue. The combination therapy approach aims to enhance the efficacy of existing treatments and address unmet needs in cancer therapy. Positive clinical data and subsequent regulatory approvals could position BI-1206 as a valuable asset in CASI's portfolio. Timeline: Ongoing clinical trials with potential for Phase III trials in the next 2-4 years.
- Commercialization of CID-103 for Multiple Myeloma: CID-103, a product in CASI's pipeline for the treatment of patients with multiple myeloma, presents a growth opportunity in the expanding market for myeloma therapies. The increasing incidence of multiple myeloma and the demand for novel treatment options drive market growth. Successful development and commercialization of CID-103 could contribute significantly to CASI's revenue stream. Timeline: Ongoing development with potential for clinical trials in the next 1-2 years.
- Strategic Partnerships and Licensing Agreements: CASI's strategy of forming partnerships and licensing agreements with companies like Juventas Cell Therapy Ltd and BioInvent International AB provides access to innovative technologies and expands its product portfolio. These collaborations can accelerate the development and commercialization of new therapies, reducing risk and leveraging external expertise. Expanding these partnerships could drive future growth for CASI. Timeline: Ongoing, with potential for new agreements in the next 1-2 years.
- Expansion in the Chinese Market: CASI's focus on the Chinese market, through distribution agreements with companies like China Resources Pharmaceutical Commercial Group International Trading Co., Ltd, offers significant growth potential. The Chinese pharmaceutical market is one of the largest and fastest-growing in the world, driven by increasing healthcare spending and a large patient population. Successfully navigating the regulatory landscape and expanding its commercial presence in China could drive substantial revenue growth for CASI. Timeline: Ongoing, with continuous efforts to expand market access and sales in China.
What Opportunities Does CASI Have?
- Expansion of CAR-T therapy (CNCT19).
- Development of BI-1206 in combination therapies.
- Growth in the Chinese pharmaceutical market.
- Acquisition or licensing of new products.
What Threats Does CASI Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from established pharmaceutical companies.
- Patent expirations.
What Are CASI's Competitive Advantages?
- Proprietary drug formulations and intellectual property.
- Strategic partnerships and licensing agreements.
- Focus on the Chinese pharmaceutical market.
- Expertise in developing and commercializing oncology therapies.
What Does CASI Do?
CASI Pharmaceuticals, Inc., established in 1991 and rebranded from EntreMed, Inc. in 2014, is a biopharmaceutical company dedicated to the development and commercialization of innovative therapeutics. Headquartered in Rockville, Maryland, CASI focuses on addressing unmet medical needs, particularly in hematological cancers. The company's marketed product, EVOMELA, an intravenous formulation of melphalan, is used as a conditioning treatment before stem cell transplantation and as a palliative treatment for multiple myeloma patients. CASI's pipeline includes CNCT19, an autologous CD19 CAR-T investigative product targeting B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). Additionally, BI-1206 is in Phase I/II trials for solid tumors and relapsed/refractory NHL, while CB-5339 is in Phase I for acute myeloid leukemia and myelodysplastic syndrome. Other pipeline products include CID-103 for multiple myeloma, Thiotepa for haemopoietic stem cell transplants, and Octreotide for acromegaly and neuroendocrine tumors. CASI strategically partners through licensing agreements with companies like Juventas Cell Therapy Ltd and BioInvent International AB, and distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd, expanding its reach and capabilities. CASI operates in China, the United States, and internationally.
What Products and Services Does CASI Offer?
- Develops and commercializes therapeutics and pharmaceutical products.
- Focuses on treatments for hematological cancers and other unmet medical needs.
- Offers EVOMELA for conditioning treatment prior to stem cell transplantation and palliative treatment for multiple myeloma.
- Develops CNCT19, a CAR-T therapy for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.
- Conducts clinical trials for BI-1206 in combination with other therapies for solid tumors and NHL.
- Advances CB-5339 in clinical trials for acute myeloid leukemia and myelodysplastic syndrome.
- Seeks regulatory approvals for its pipeline products in China, the United States, and internationally.
How Does CASI Make Money?
- Develops pharmaceutical products internally and through licensing agreements.
- Commercializes products through its own sales force and distribution agreements.
- Generates revenue from product sales, primarily EVOMELA.
- Invests in research and development to expand its product pipeline.
What Industry Does CASI Operate In?
CASI Pharmaceuticals operates within the competitive biotechnology industry, characterized by high R&D spending, lengthy regulatory approval processes, and intense competition. The global biotechnology market is projected to reach significant growth in the coming years, driven by advancements in genomics, personalized medicine, and novel drug delivery systems. CASI's focus on hematological cancers positions it within a growing segment, but it faces competition from larger pharmaceutical companies and specialized biotech firms. The company's strategic partnerships and focus on the Chinese market provide a potential edge in navigating the complex regulatory landscape and accessing a large patient population.
Who Are CASI's Key Customers?
- Hospitals and medical centers.
- Oncologists and hematologists.
- Patients with hematological cancers, such as multiple myeloma, leukemia, and lymphoma.
- Stem cell transplant centers.
Company Profile
CASI Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Beijing, US. The company is led by CEO David A. Cory. CASI has traded publicly since 1996.
CASI Pharmaceuticals, Inc. Financial Trajectory
CASI Pharmaceuticals, Inc. (CASI) reported $3.1M in revenue for Q3 2025, a decline of 26.3% compared to the prior quarter. The company recorded a net loss of $10.9M, with diluted EPS of $-0.68. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, CASI averaged $-0.79 in diluted EPS.
How CASI Pharmaceuticals, Inc. Is Valued
CASI Pharmaceuticals, Inc. carries a market capitalization of $2.33M, placing it in the micro-cap category. Relative to its peer group, CASI's quantitative score of 47/100 is below the peer average of 86/100.
ROE 204%Key Financial Metrics
Return on equity for CASI Pharmaceuticals, Inc. stands at 203.9%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.27 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 3/9Financial Health
CASI Pharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -47.99 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project CASI Pharmaceuticals, Inc. revenue of about $70.4M for fiscal 2026, with EPS near $-1.41.
CASI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in CASI's future, indicating that those closest to the company believe in its potential.
- Community sentiment has shifted positively as recent clinical trial updates show promise for their pipeline, attracting more interest from investors.
- Positive media coverage highlighting CASI's innovative approaches in oncology has enhanced its market perception, drawing attention from both retail and institutional investors.
- Analysts are noting the strategic partnerships CASI has formed, which can accelerate drug development and expand market reach, further boosting investor optimism.
Bear Case
- Concerns over the competitive landscape in the biotech sector are growing, with many investors wary of CASI's ability to stand out among numerous players.
- Recent social sentiment has shown some skepticism regarding the timelines for CASI's drug approvals, leading to uncertainty among potential investors.
- Insider selling activity has raised red flags for some community members, suggesting that not all insiders are confident in the company's immediate prospects.
- Market reactions to CASI's earnings reports have been lukewarm, indicating that investors may be cautious about the company's financial health moving forward.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $3M | -$11M | -$0.68 |
| Q2 2025 | $4M | -$13M | -$0.86 |
| Q1 2025 | $6M | -$11M | -$0.69 |
| Q4 2024 | $13M | -$14M | -$0.93 |
Based on FMP financials and quantitative analysis
CASI Latest News
No recent news available for CASI.
CASI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CASI.
Price Targets
Wall Street price target analysis for CASI.
CASI MoonshotScore
What does this score mean?
The MoonshotScore rates CASI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest CASI Pharmaceuticals, Inc. Analysis
Leadership: David A. Cory
Chief Executive Officer
David A. Cory serves as the Chief Executive Officer of CASI Pharmaceuticals, Inc. His background includes extensive experience in the biopharmaceutical industry, with a focus on oncology drug development and commercialization. He has held leadership positions in various pharmaceutical companies, contributing to the development and launch of several successful products. His expertise spans clinical development, regulatory affairs, and commercial strategy.
Track Record: Under David Cory's leadership, CASI Pharmaceuticals has focused on advancing its pipeline of oncology therapies, particularly CNCT19 and BI-1206. He has overseen the expansion of the company's strategic partnerships and licensing agreements, strengthening its product portfolio. Key milestones include the continued commercialization of EVOMELA and the progress of clinical trials for its lead drug candidates.
Common Questions About CASI (Healthcare)
What does CASI Pharmaceuticals, Inc. do?
CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics, primarily for the treatment of hematological cancers. The company's marketed product, EVOMELA, is used in stem cell transplantation and multiple myeloma treatment. CASI's pipeline includes CAR-T therapy (CNCT19) and other drug candidates in clinical trials, targeting unmet medical needs in oncology. The company operates in China, the United States, and internationally, leveraging strategic partnerships and licensing agreements to expand its reach and capabilities.
What do analysts say about CASI stock?
Analyst coverage of CASI Pharmaceuticals, Inc. is limited given its small market capitalization. General sentiment reflects cautious optimism regarding the potential of its pipeline products, particularly CNCT19 and BI-1206. Key valuation metrics are influenced by the success of clinical trials and regulatory approvals. Growth considerations include the company's ability to secure partnerships, expand its market presence in China, and manage its operating expenses. The lack of profitability is a concern that requires monitoring.
What are the main risks for CASI?
The main risks for CASI Pharmaceuticals, Inc. include clinical trial failures, which could significantly impact the value of its pipeline assets. Regulatory hurdles and delays in obtaining approvals for new therapies pose additional challenges. Competition from larger pharmaceutical companies with greater resources and established market presence is a significant concern. The company's reliance on strategic partnerships and licensing agreements also introduces risk, as these agreements could be terminated or altered. Economic and political instability in China could impact market access and commercial operations.
How does CASI Pharmaceuticals, Inc. manage patent expiration risks?
CASI Pharmaceuticals, Inc. manages patent expiration risks through a combination of strategies, including developing new formulations and indications for existing products, securing patent extensions where possible, and actively monitoring the competitive landscape for potential biosimilar threats. The company also invests in research and development to create novel therapies with new patent protection, diversifying its portfolio and reducing reliance on individual products facing patent expiration. Strategic partnerships and licensing agreements can also provide access to new technologies and intellectual property, mitigating patent expiration risks.
What are the key growth opportunities for CASI in healthcare?
CASI Pharmaceuticals, Inc.'s key growth opportunities in healthcare lie in the successful development and commercialization of its pipeline products, particularly CNCT19, a CAR-T therapy for hematological malignancies. Expansion into new therapeutic areas, such as solid tumors, through the development of BI-1206 in combination therapies, also presents a significant growth opportunity. Furthermore, leveraging its presence in the Chinese market and expanding its commercial reach through strategic partnerships and distribution agreements can drive revenue growth. The company's focus on innovative therapies and strategic collaborations positions it for future success in the competitive healthcare landscape.
What are the key factors to evaluate for CASI?
CASI Pharmaceuticals, Inc. (CASI) holds an AI score of 47/100 (low). Not financial advice.
How frequently does CASI data refresh on this page?
CASI prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CASI's recent stock price performance?
CASI Pharmaceuticals, Inc. (CASI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product pipeline targeting hematological cancers. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Financial data is limited and may not be fully up-to-date.